Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Conditions

Cervical Cancer, Head and Neck Cancer, Ovarian Cancer, Sarcoma, Triple-Negative Breast Cancer, Vulva Cancer

Keywords

Immunological biomarkers, molecular profil, Circulating tumor DNA (ctDNA)

Brief summary

SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.

Detailed description

Patients will have blood and +/- tumor samples at the following times : 1. if eligible for surgery : * at surgery (blood + tumor and nodes) * after surgery (blood) * 6 months after surgery if non recurrence (Blood) * before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes if possible) * before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood) * at progression (blood + tumor biopsie and nodes if possible) 2. if eligible for neoadjuvant chemotherapy : * before neoadjuvant therapy (blood + tumor biopsie and nodes) * during neoadjuvant therapy (post cycle 1) (blood) * at the time of surgery (blood + tumor and nodes) * 6 months after surgery if non recurrence (Blood) * before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes) * before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood) * at progression (blood + tumor biopsie and nodes)

Joey Martin, Constance Lamy, Houcine Hamidi, Nicolas Merle, Idris Boudhabhay et al. (20 authors)

Journal of Clinical Oncology2026-05-28

10.1200/jco.2026.44.16_suppl.e18049

Internal validation strategy for high dimensional prognosis model: A simulation study and application to transcriptomic in head and neck tumors.

Dubray-Vautrin A, Gravrand V, Marret G, Lamy C, Klijanienko J, Vacher S, Ahmanache L, Kamal M, Choussy O, Servant N, Dupain C, Le Tourneau C, Mullaert J.

2025-09-03

10.1016/j.csbj.2025.08.035

Abstract 1252: Evolution of transcriptomic and epigenomic intra-tumor heterogeneity in high-grade serous ovarian cancer with chemotherapy

Yuna Landais, Juliette Bertorello, Marta Puerto, Brett A. Simon, Amélie Roehrig et al. (11 authors)

Cancer Research2025-04-21

10.1158/1538-7445.am2025-1252

Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.

Marret G, Lamy C, Vacher S, Cabel L, Séné M, Ahmanache L, Courtois L, El Beaino Z, Klijanienko J, Martinat C, Servant N, Kamoun C, Halladjian M, Bronzini T, Balsat C, Laes JF, Prévot A, Sauvage S, Lienard M, Martin E, Genin B, Badois N, Lesnik M, Dubray-Vautrin A, Choussy O, Ghanem W, Taouachi R, Planchon JM, Bièche I, Le Tourneau C, Kamal M.

2024-11-294 citations

10.1016/j.oraloncology.2024.107111

Abstract 1620: Multiregion spatial sequencing of early-stage head and neck squamous cell carcinoma revealed theranostic intratumor heterogeneity

Grégoire Marret, Sophie Vacher, Constance Lamy, Ladidi Ahmanache, Laura Courtois et al. (24 authors)

Cancer Research2024-03-22

10.1158/1538-7445.am2024-1620

Abstract 3363: Spatial and longitudinal tumor heterogeneity in head and neck squamous cell carcinoma patients treated with primary surgery

Grégoire Marret, Constance Lamy, Sophie Vacher, Mathieu Séné, Ladidi Ahmanache et al. (30 authors)

Cancer Research2023-04-04

10.1158/1538-7445.am2023-3363

Interventions

PROCEDURETumor biopsies / Tumor surgery

Tumoral tissues samples must be collected at different times points : * at the time of surgery * before first cycle of adjuvant treatment (if possible) * at progression (if possible) OR * before neoadjuvant therapy * at the time of surgery * before first cycle of adjuvant treatment (if possible) * at progression (if possible)

PROCEDUREBlood withdrawal

Blood samples must be collected at different times points : * at the time of surgery or before the beginning of chemoradiotherapy * after surgery or after chemoradiotherapy * 6 months after surgery if non recurrence * before first cycle of adjuvant treatment or before radiotherapy * before second cycle of adjuvant treatment or after radiotherapy * at progression OR * before neoadjuvant therapy * during neoadjuvant therapy (post cycle 1) * at the time of surgery * 6 months after surgery if non recurrence * before first cycle of adjuvant treatment or before radiotherapy * before second cycle of adjuvant treatment or after radiotherapy * at progression

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Tumor types : 1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy 2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy 3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery 4. Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2). 5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment 2. Male or female patients ≥ 18 years of age 3. Signed informed consent

Exclusion criteria

1. Male or female patients ≤18 years old 2. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 3. Individually deprived of liberty or placed under the authority of a tutor 4. Patients not affiliated to the Social Security System

Design outcomes

Primary

Measure	Time frame
Correlation between tumor molecular/immunological profile and Baseline clinicobiological features	up to 6 months

Secondary

Measure	Time frame
Correlation between disease recurrence and molecular and/or immunological biomarkers	up to 24 months
Correlation between genomic alterations and immune parameters	up to 24 months
Correlation between mutations load and immune parameters	up to 24 months
Correlation between ctDNA levels, de novo mutations in ctDNA and immune	up to 24 months
For cervical cancer patient, correlation between ctDNA levels and kinetics, and prognosis, prediction of recurrence	up to 24 months

Countries

France

Contacts

CONTACTAnne-Sophie PLISSONNIER

drci.promotion@curie.fr01 47 11 23 78

PRINCIPAL_INVESTIGATOREdith BORCOMAN, Prof.

Institut Curie

Outcome results

None listed